[go: up one dir, main page]

WO2010112034A3 - Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies - Google Patents

Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies Download PDF

Info

Publication number
WO2010112034A3
WO2010112034A3 PCT/DK2010/050077 DK2010050077W WO2010112034A3 WO 2010112034 A3 WO2010112034 A3 WO 2010112034A3 DK 2010050077 W DK2010050077 W DK 2010050077W WO 2010112034 A3 WO2010112034 A3 WO 2010112034A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
expression
methods
cxch
neurodegenerative disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2010/050077
Other languages
English (en)
Other versions
WO2010112034A2 (fr
Inventor
Poul Henning Jensen
Christine Lund Kragh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of WO2010112034A2 publication Critical patent/WO2010112034A2/fr
Publication of WO2010112034A3 publication Critical patent/WO2010112034A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode de traitement d'un trouble neurodégénératif, un composé inhibant ou régulant à la baisse l'expression d'un gène sélectionné dans le groupe constitué de Gadd45a, Gadd45b, Gadd45g, Nfkbia, Bbc3/PUMA, Ninji, Ccl2, Ccl7, Clcfl, Csfl, CxcH, Cxcl2, CxcH 0, IL6, Bhlhb2, Camkk2, Duspi, Lphn2, RiI, Hmoxi, Hspal a, Myd1 16, Srxni, Egr1, Fos, FosL, Hes1, KIfI O, Myc, Kpnai, SId 5a4, Slc35b2, Stx1 1, et Nudt18. L'invention concerne également des compositions pharmaceutiques destinées à être utilisées pour de telles méthodes de traitement, ainsi que des kits de diagnostic comprenant un élément de détection permettant de détecter l'expression des gènes impliqués dans des troubles neurodégénératifs. L'invention concerne en outre un procédé d'identification de nouveaux composés pour le traitement d'un trouble neurodégénératif, qui est basé sur la détection des niveaux d'expression des gènes en cause.
PCT/DK2010/050077 2009-04-02 2010-04-06 Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies Ceased WO2010112034A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900456 2009-04-02
DKPA200900456 2009-04-02

Publications (2)

Publication Number Publication Date
WO2010112034A2 WO2010112034A2 (fr) 2010-10-07
WO2010112034A3 true WO2010112034A3 (fr) 2011-05-05

Family

ID=42828754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2010/050077 Ceased WO2010112034A2 (fr) 2009-04-02 2010-04-06 Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies

Country Status (1)

Country Link
WO (1) WO2010112034A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740722B (zh) * 2014-01-02 2016-01-20 温州医科大学 抑制视网膜色素上皮细胞凋亡的shRNA及其应用
US20250290935A1 (en) * 2021-06-30 2025-09-18 Shenzhen Institutes Of Advanced Technolgy Chinese Academy Of Sciences Marker of alzheimer's disease and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073212A2 (fr) * 2001-03-12 2002-09-19 Isis Innovation Limited Analyses diagnostiques destinees a la maladie d'alzheimer
WO2005017143A1 (fr) * 2003-08-13 2005-02-24 Garvan Institute Of Medical Research Diagnostic et traitement des maladies neurodegeneratives, faisant intervenir le gene de proteine tau associee aux microtubules (mapt)
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
WO2007127273A2 (fr) * 2006-04-24 2007-11-08 Alltech, Inc. Procédés et compositions permettant de modifier la fonction cellulaire
WO2009021708A2 (fr) * 2007-08-13 2009-02-19 Baxter International Inc. Modulation par des immunoglobulines intraveineuses (ivig) de chimiokines pour le traitement de la sclérose en plaques, de la maladie d'alzheimer et de la maladie de parkinson

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US567A (en) 1838-01-09 Machine for r-uibbii
US4816A (en) 1846-10-17 Bell machinery for hotels
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (fr) 1991-06-14 1992-12-23 Genpharm International, Inc. Animaux transgeniques non humains presentant une deficience immunitaire
WO1993001227A1 (fr) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
CA2150262C (fr) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
CA2117477C (fr) 1992-12-11 2001-06-12 Peter S. Mezes Anticorps multivalents a chaine simple
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
NZ517372A (en) 1999-07-29 2004-04-30 Medarex Inc Human monoclonal antibodies to HER2/neu
EP1354034B8 (fr) 2000-11-30 2008-06-18 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073212A2 (fr) * 2001-03-12 2002-09-19 Isis Innovation Limited Analyses diagnostiques destinees a la maladie d'alzheimer
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
WO2005017143A1 (fr) * 2003-08-13 2005-02-24 Garvan Institute Of Medical Research Diagnostic et traitement des maladies neurodegeneratives, faisant intervenir le gene de proteine tau associee aux microtubules (mapt)
WO2007127273A2 (fr) * 2006-04-24 2007-11-08 Alltech, Inc. Procédés et compositions permettant de modifier la fonction cellulaire
WO2009021708A2 (fr) * 2007-08-13 2009-02-19 Baxter International Inc. Modulation par des immunoglobulines intraveineuses (ivig) de chimiokines pour le traitement de la sclérose en plaques, de la maladie d'alzheimer et de la maladie de parkinson

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOUERY ELIANE ET AL: "Mutations in TREM2 lead to pure early-onset dementia without bone cysts.", HUMAN MUTATION SEP 2008 LNKD- PUBMED:18546367, vol. 29, no. 9, September 2008 (2008-09-01), pages E194 - E204, XP009145052, ISSN: 1098-1004 *
MOMOSE Y ET AL: "ASSOCIATION STUDIES OF MULTIPLE CANDIDATE GENES FOR PARKINSON'S DISEASE USING SINGLE NUCLEOTIDE POLYMORPHISMS", ANNALS OF NEUROLOGY, JOHN WILEY AND SONS, BOSTON, US, vol. 51, no. 1, 1 January 2002 (2002-01-01), pages 133 - 136, XP008023548, ISSN: 0364-5134, DOI: DOI:10.1002/ANA.10079 *
ROCCHI A ET AL: "Causative and susceptibility genes for Alzheimer's disease: A review.", BRAIN RESEARCH BULLETIN, vol. 61, no. 1, 30 June 2003 (2003-06-30), pages 1 - 24, XP002625229, ISSN: 0361-9230 *
SEIDMAN S ET AL: "ANTISENSE TECHNOLOGIES HAVE A FUTURE FIGHTING NEURODEGENERATIVE DISEASES", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 9, no. 4, 1 August 1999 (1999-08-01), pages 333 - 340, XP000984531, ISSN: 1087-2906 *

Also Published As

Publication number Publication date
WO2010112034A2 (fr) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2010117829A3 (fr) Micro-arn d'expression différentielle utilisés comme biomarqueurs du diagnostic du syndrome de sjögren et traitement associé
WO2011107482A3 (fr) Méthode de diagnostic de l'obésité
WO2009108856A3 (fr) Signatures de microarn associées à la leucémie lymphoïde chronique humaine (llc) et leurs utilisations
WO2010057112A3 (fr) Variants génétiques intervenant dans la cognition humaine et leurs procédés d'utilisation comme cibles diagnostiques et thérapeutiques
WO2010033773A3 (fr) Utilisations diagnostiques, pronostiques et thérapeutiques de mir dans des voies adaptatives et/ou des voies pathologiques
WO2010062377A3 (fr) Procédés et compositions pour la détection et le traitement de l’éclampsie
WO2011107481A3 (fr) Méthode de diagnostic de maladies intestinales inflammatoires
WO2011008696A3 (fr) Procédés de diagnostic et compositions pour traitement d'un cancer
WO2012125872A3 (fr) Procédés de diagnostic et de traitement de la maculopathie vasculaire associée et des symptômes correspondants
WO2008095492A3 (fr) Méthode de diagnostic de plaques athéroscléreuses par mesure du récepteur cd36
WO2011091065A8 (fr) Nanostructures synthétiques comprenant des acides nucléiques et/ou d'autres entités
WO2011078797A3 (fr) Oligonucléotides antisens et utilisations de ceux-ci
WO2009116861A3 (fr) Diagnostic du syndrome métabolique pré-symptomatique
EP2540840A3 (fr) Variants génétiques du CHR16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2010065630A3 (fr) Compositions et procédés de traitement d'une néoplasie hépatique
WO2010059242A3 (fr) Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation
WO2014096418A3 (fr) Microarn en tant qu'agents thérapeutiques et biomarqueurs pour l'épilepsie
WO2009120712A3 (fr) Compositions et procédés pour diagnostiquer et traiter un mélanome
EP2716770A3 (fr) Sondes d'acide nucléique pour la détection des bactéries infectieuses
WO2010112034A3 (fr) Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies
Villareal et al. Deterioration of neuroimmune homeostasis in Alzheimer’s Disease patients who survive a COVID-19 infection
WO2008065682A3 (fr) Variantes génétiques de susceptibilité au diabète mellitus de type 2
WO2008138928A3 (fr) Diagnostic d'une tolérance immunitaire à une greffe
WO2006128041A3 (fr) Compositions et procedes destines a traiter ou a prevenir un neoplasme chimiomoresistant
WO2011084548A8 (fr) Méthodes et compositions permettant de dépister la forme familiale récessive de la fsgs et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10713113

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10713113

Country of ref document: EP

Kind code of ref document: A2